Permeation Enhancers Dramatically Boost Oral Absorption of Peptide Drugs in Rats
Background
Many therapeutic peptides, like enalaprilat (an ACE inhibitor prodrug) and hexarelin (a growth hormone secretagogue), suffer from poor oral bioavailability due to their large size and susceptibility to enzymatic degradation in the gastrointestinal tract. This necessitates inconvenient parenteral (injectable) administration. Improving their intestinal absorption is crucial for developing oral formulations. This study specifically investigates how various paracellular permeation enhancers can increase the intestinal permeability of these two distinct peptide drugs in a rat model.
Results
The study demonstrated significant improvements in the intestinal permeability of both peptides with the use of specific enhancers. For enalaprilat, sodium caprate proved most effective, increasing its apparent permeability coefficient (Papp) by a remarkable 4.3-fold (from a baseline of 0.8 x 10^-6 cm/s to 3.44 x 10^-6 cm/s, p<0.001). EDTA also enhanced enalaprilat permeability by 2.1-fold. Sodium caprate was particularly potent, boosting hexarelin permeability by an impressive 5.8-fold (from 0.6 x 10^-6 cm/s to 3.48 x 10^-6 cm/s, p<0.001), suggesting a strong interaction with tight junctions. Chitosan showed a modest 1.5-fold increase for both peptides, indicating its potential but lesser efficacy compared to sodium caprate. These enhancements were significantly higher than control groups, which showed no change in permeability over the study duration.
Why It Matters
This research provides compelling evidence that paracellular permeation enhancers can dramatically improve the oral absorption of peptide drugs, potentially paving the way for non-injectable formulations. The substantial increases in permeability observed, particularly with sodium caprate, highlight its promise as an excipient in future oral peptide drug delivery systems. This could lead to the development of convenient oral dosage forms for peptides currently administered via injection, significantly improving patient compliance and quality of life. Future steps would involve optimizing enhancer concentrations, evaluating long-term safety and toxicity in preclinical models, and eventually progressing to human clinical trials (Phase I/II) to confirm efficacy and safety in vivo.